APA (7th ed.) Citation

OG, C., KL, O., EG, D., CH, G., JC, J., JP, G., . . . D, G. (2023). Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers. Clinical lymphoma, myeloma & leukemia, 23(11), e386. https://doi.org/10.1016/j.clml.2023.08.004

Chicago Style (17th ed.) Citation

OG, Cantu-Rodriguez, et al. "Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers." Clinical Lymphoma, Myeloma & Leukemia 23, no. 11 (2023): e386. https://doi.org/10.1016/j.clml.2023.08.004.

MLA (9th ed.) Citation

OG, Cantu-Rodriguez, et al. "Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers." Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 11, 2023, p. e386, https://doi.org/10.1016/j.clml.2023.08.004.